Furthermore, 5% of the CSF samples, which were collected from a patient with primary CNS lymphoma on day 2 after the fifth glofitamab administration, showed an increase in the quantity of CD25 and CD69+ T cells. Here, CD69 is linked to primary central nervous system lymphoma.